Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q4 EPS of ($0.03), $0.21 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $11.03 million versus the consensus estimate of $3.83 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.